AU3322593A - Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone - Google Patents

Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone

Info

Publication number
AU3322593A
AU3322593A AU33225/93A AU3322593A AU3322593A AU 3322593 A AU3322593 A AU 3322593A AU 33225/93 A AU33225/93 A AU 33225/93A AU 3322593 A AU3322593 A AU 3322593A AU 3322593 A AU3322593 A AU 3322593A
Authority
AU
Australia
Prior art keywords
acid
day
bisphosphonate
parathyroid hormone
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU33225/93A
Other languages
English (en)
Inventor
Rogely Waite Boyce
Ann Dunbar Geddes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Pharmaceuticals Inc
Original Assignee
Procter and Gamble Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Pharmaceuticals Inc filed Critical Procter and Gamble Pharmaceuticals Inc
Publication of AU3322593A publication Critical patent/AU3322593A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33225/93A 1991-12-17 1992-12-15 Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone Withdrawn AU3322593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80962091A 1991-12-17 1991-12-17
US809620 1991-12-17

Publications (1)

Publication Number Publication Date
AU3322593A true AU3322593A (en) 1993-07-19

Family

ID=25201804

Family Applications (2)

Application Number Title Priority Date Filing Date
AU33225/93A Withdrawn AU3322593A (en) 1991-12-17 1992-12-15 Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
AU30226/92A Ceased AU663348B2 (en) 1991-12-17 1992-12-16 Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU30226/92A Ceased AU663348B2 (en) 1991-12-17 1992-12-16 Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone

Country Status (18)

Country Link
US (1) US5616560A (enExample)
EP (1) EP0618805A1 (enExample)
JP (1) JPH07502507A (enExample)
AU (2) AU3322593A (enExample)
BR (1) BR9206941A (enExample)
CA (1) CA2124792C (enExample)
CZ (1) CZ282889B6 (enExample)
FI (1) FI942884A7 (enExample)
HU (1) HUT68010A (enExample)
IL (1) IL104108A (enExample)
MA (1) MA23079A1 (enExample)
MX (1) MX9207349A (enExample)
NO (1) NO942241D0 (enExample)
NZ (1) NZ246456A (enExample)
RU (2) RU2112515C1 (enExample)
SK (1) SK74594A3 (enExample)
WO (1) WO1993011786A1 (enExample)
ZA (1) ZA929758B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663348B2 (en) * 1991-12-17 1995-10-05 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4859493A (en) * 1992-10-09 1994-05-09 Upjohn Company, The Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
EP0779812A4 (en) * 1994-09-09 1997-09-10 Procter & Gamble Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
JPH10505091A (ja) * 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症用のホスホネート及び副甲状腺ホルモン
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
JP3796693B2 (ja) * 1994-12-28 2006-07-12 ガドール エス アー オルパドロネートからなる骨塊同化組成物
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
RU2155588C2 (ru) * 1998-10-16 2000-09-10 Общество с ограниченной ответственностью "Институт фармацевтических реактивов РЕФАРМ" Способ увеличения массы костной ткани при переломах
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
AU4217299A (en) 1998-11-30 2000-06-19 General Hospital Corporation, The Pth1r and pth3r receptors, methods and uses thereof
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
RU2387451C2 (ru) 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
RU2219933C1 (ru) * 2002-07-22 2003-12-27 Волова Лариса Теодоровна Способ стимуляции остеогенеза
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
DK1635875T3 (da) * 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
JP4871128B2 (ja) 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
AU2004264899A1 (en) * 2003-08-06 2005-02-24 Innophos, Inc. Method for promoting bone growth
US20050043359A1 (en) * 2003-08-20 2005-02-24 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
RU2273493C1 (ru) * 2004-10-15 2006-04-10 Валерий Николаевич Зеленков Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты)
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
CA2687903C (en) * 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CN104072606B (zh) * 2007-08-01 2017-09-22 总医院有限公司 利用g蛋白偶联受体和相关组合物的筛选方法
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
WO2016163886A2 (en) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
ES3009869T3 (en) 2018-10-29 2025-03-31 Asahi Kasei Pharma Corp An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663348B2 (en) * 1991-12-17 1995-10-05 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone

Also Published As

Publication number Publication date
FI942884L (fi) 1994-06-16
RU2112515C1 (ru) 1998-06-10
CA2124792C (en) 2000-07-04
MA23079A1 (fr) 1993-07-01
CZ282889B6 (cs) 1997-11-12
CZ147794A3 (en) 1994-12-15
RU94031209A (ru) 1996-07-27
WO1993011786A1 (en) 1993-06-24
AU663348B2 (en) 1995-10-05
CA2124792A1 (en) 1993-06-24
MX9207349A (es) 1993-12-01
FI942884A0 (fi) 1994-06-16
IL104108A (en) 1999-09-22
HUT68010A (en) 1995-05-29
US5616560A (en) 1997-04-01
NO942241L (enExample) 1994-08-09
NO942241D0 (no) 1994-06-15
RU2104699C1 (ru) 1998-02-20
IL104108A0 (en) 1993-05-13
ZA929758B (en) 1993-09-10
SK74594A3 (en) 1995-01-12
FI942884A7 (fi) 1994-06-16
HU9401798D0 (en) 1994-09-28
BR9206941A (pt) 1995-05-02
NZ246456A (en) 1997-03-24
AU3022692A (en) 1993-06-24
JPH07502507A (ja) 1995-03-16
EP0618805A1 (en) 1994-10-12

Similar Documents

Publication Publication Date Title
US5616560A (en) Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
EP0573604B1 (en) Methods for the treatment of osteoporosis
US5366965A (en) Regimen for treatment or prophylaxis of osteoporosis
AU686458B2 (en) Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
AU686019B2 (en) Phosphonates and parathyroid hormone for osteoporosis
JP2005514400A (ja) 骨疾患の治療方法
EP0804202A1 (en) Estrogens and parathyroid hormone for treating osteoporosis